Friday , July 1 2022

The study identifies the genetic control of the deadly prostate cancer


The study identifies the genetic control of the deadly prostate cancer

Graphically, it shows the lifting activity of a transcriptional network, in patients with Onecut2 molecular tumors, against prostate cancer hormone therapy (above purple bar) compared to other types. (Michael Freeman, Ph.D.) Credit: Nature Publishing Group

A new study has identified a new molecular control of the deadly prostate cancer with a molecule that can be used to attack. Discovery lab mice were made. If they were confirmed in humans, they would be the most effective way of controlling some types of prostate cancer, U.S. The second reason for male cancer is cancer.

Men with prostate cancer tumors usually diagnose many years of survival after surgery, radiation therapy or treatment. But when the cancer is exposed to other parts of the body, the fewer men suffer from hormonal therapy, the prognosis is poor, and after a third diagnosis they last longer than five years. More than 29,000 men in the United States have died of prostate cancer every year, according to the American Cancer Society.

"To prevent prostate cancer, we need fresh strategies for coffin due to their metastasizing and hormonal treatment," said Michael Freeman, Ph.D., Assistant Director of the Cancer Biology Program at Samuel Oschin Cancer Institute in Cedars-Sinai. Hormone therapy hormones block male activity that promotes the most common prostate cancer type.

He is the author of a multicultural study published in Freeman magazine Natural Medicine. The first authors were Mirja Rotinen, Ph.D., and Dr. Sungyong You, Assistant Professor of Surgery and Biomedical Sciences, both at Cedars-Sinai.

For research, a large database analyzed the genetic and molecular data of cancer patients. Onecut2 demonstrated a rise in the activity of the molecule in tumors of prostate cancer patients. Onecut2 is a transcription factor that requires the body to perform certain proteins.

The group Onecut2 interfered with the activity of androgen receptors in the therapeutic hormone therapeutic prostate cancer. This process may have an increase in cancer hormones. At the same time, Onecut2 promoted a cancer cell to change the more aggressive type of hormone therapy. "The twin actions of Onecut2 show how prostate cancer can help prevent hormone therapy and become more aggressive," said Freeman, Professor of Surgery and Biomedicine Sciences.

Additional experiments including human tissue samples, pharmaceutical databases and laboratory animals, researchers identified a compound, CSRM617, damaged Onecut2. CSRM617 has been shown to reduce the size of prostatic cancer metastatic mice. "Our research suggested that Onecut2 is a lethal prostate cancer regulator that can be useful therapeutic purposes, extends cancer cancer and avoids third-thirds of hormone therapies," Freeman said.

Freeman is the author of the latest research Cancer Research He identified a new method for measuring prostate cancer aggression. This method is how stable the shape of the cancer cell nuclei. Instability spread with the type of cancer. The researchers also found that the instability of the nucleus was detected in the blood through cells extracted through the cell. These findings can less invasive techniques for potentially dangerous prostate cancer and monitor their progress through blood samples, the research team said.

"These findings are the work of shifting Cedars-Sinai cancer into cancer," said Dan Theodorescu, MD, Ph.D., director of the cancer institute. "Researchers find our scientific discovery in the clinical development of new therapies that will affect patients."

Explore more:
Surgery and combination therapy optimizes the results of aggressive prostate cancer treatment

More information:
Mirina Rotinen et al., ONECUT2, is a major regulator of prostate cancer, the androgen axis, Natural Medicine (2018). DOI: 10.1038 / s41591-018-0241-1

Source link